ChiaPorteraMD

Oncology • Vacaville, CA

Sr. Medical Director

Join to view full profile

Dr. Portera is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Portera's full profile

Already have an account?

Office
P.O. Box 5791
Vacaville, CA 95696

Education & Training

National Institutes of Health Clinical CenterFellowship, Medical Oncology, 2005 - 2008
Wake Forest School of Medicine of Wake Forest Baptist Medical CenterClass of 2002

Certifications & Licensure

CA State Medical License 2009 - 2019
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology

Clinical Trials

Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab Start of enrollment: 2005 Dec 01
Completed
Phase 2
A Study of Dulanermin Administered in Combination With Camptosar®/Erbitux® Chemotherapy or FOLFIRI (With or Without Bevacizumab) in Subjects With Previously Treated Metastatic Colorectal Cancer Start of enrollment: 2006 Jul 01
Completed
Phase 1
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g) Start of enrollment: 2009 May 01
Completed
Phase 1
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer Start of enrollment: 2009 May 01
Completed
Phase 1
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma Start of enrollment: 2010 Oct 01
Completed
Phase 1
A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma Start of enrollment: 2011 Jul 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

44 citations
A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.
Zev A. Wainberg, Wells A. Messersmith, Parvin F. Peddi, Amy V. Kapp, Avi Ashkenazi
Clinical Colorectal Cancer. 2013-12-01
11 citations
The Heart of the Matter
Chia C. Portera, Sandra M. Swain
Journal of Clinical Oncology. 2007-09-01
112 citations
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast ...
Chia C. Portera, Janice M. Walshe, Douglas R. Rosing, Neelima Denduluri, Arlene Berman
Clinical Cancer Research. 2008-05-01